Stem cells are extraordinary cells with the unique ability to self-renew and differentiate into specialized cell types, playing a vital role in growth, development, and tissue repair. Among these, induced pluripotent stem cells (iPSCs) stand out as a transformative innovation. Derived from somatic (non-reproductive) cells, iPSCs are reprogrammed into a pluripotent state, enabling them to differentiate into any cell type in the human body. This groundbreaking technology holds immense promise for understanding disease mechanisms, developing targeted therapies, and advancing health outcomes.
At the Coriell Institute, we bring unparalleled expertise to every stage of stem cell research. Our state-of-the-art core capabilities are designed to establish, maintain, characterize, and bank premium-quality human iPSC lines, non-human primate (NHP) stem cells, and mouse embryonic stem cells (mESCs). Our laboratories adhere to ISO 9001:2015-certified standard operating procedures, ensuring that all processes meet stringent quality standards. Each characterized iPSC line is accompanied by a comprehensive Certificate of Analysis (CofA) to guarantee reliability and transparency.
iPSCs are revolutionizing research and medical science by enabling:
The Coriell Institute leverages its expertise to deliver iPSC models that meet the exacting needs of researchers, advancing groundbreaking discoveries in these fields.
